Apr 3 |
FibroGen falls after early-stage data for prostate cancer drug
|
Apr 3 |
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
|
Apr 2 |
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
|
Mar 28 |
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
|
Mar 27 |
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
|
Mar 26 |
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
|
Mar 20 |
3 Nightmare Nasdaq Stocks Not Worth Holding Another Day
|
Mar 20 |
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
|
Mar 20 |
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
|
Mar 19 |
Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
|